Compare Cassava Sciences Inc (FLNA) vs Alliant Energy Corporation (LNT) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

LNT trades at $76.31, down 0.42% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported Q1 2026 EPS of $0.82, beating estimates, with revenue growth and a net income margin of 18.58%. Recent news highlights a $13.4 billion clean energy investment plan targeting 5-7% annual earnings growth, supported by rising data center demand.

The outlook for LNT is positive, driven by strategic capital investments and regulatory support for utilities. Key opportunities include earnings growth from data center expansion and renewable projects, while risks involve execution of large-scale investments and rising debt levels, with the debt-to-asset ratio increasing to 48.48% in 2025.